Amphion Innovations PLC Polarean update

TIDMAMP

Amphion Innovations PLC

23 August 2018

Amphion Innovations plc

("Amphion" or "the Company")

Polarean Update

London and New York, 23 August 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc ("Polarean") has announced that the first patient has been enrolled in its Phase III FDA clinical trial which aims to demonstrate non-inferiority of the Company's drug-device combination, using hyperpolarised 129-Xenon (129Xe) gas MRI, against an approved comparator.

This news means that Polarean is now in the process of its Phase III clinical trial. Polarean is listed on the AIM market of the London Stock Exchange under the ticker POLX.

Amphion currently holds c. 17 million shares, equivalent to 21.7% of the enlarged Share Capital of Polarean.

For further information please contact:

 
 Amphion Innovations                                  Tel: +1 (212) 210 6224 
 Charlie Morgan 
 
 Panmure Gordon Limited (Nominated Adviser                    Tel: +44 (0)20 
  and Corporate Broker)                                            7886 2500 
 Freddy Crossley / Ryan McCarthy / Emma 
  Earl (Corporate Finance) 
 Charlie Leigh-Pemberton (Corporate 
  Broking) 
 
 Northland Capital Partners Limited (Joint               Tel: +44 (0)20 3861 
  Corporate Broker)                                                     6625 
 David Hignell (Corporate Finance) 
 Vadim Alexandre (Corporate Broking) 
 
 Walbrook PR                                     Tel: +44 (0)20 7933 8780 or 
 Anna Dunphy / Paul McManus                           amphion@walbrookpr.com

About Amphion Innovations plc - www.amphionplc.com

Amphion Innovations is a developer of medical, life science and technology businesses. We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRALLFLSTTIVFIT

(END) Dow Jones Newswires

August 23, 2018 10:20 ET (14:20 GMT)

Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2024 to May 2024